Showing 111-120 of 328 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Safety and efficacy assessment of Tegoprubart and calcineurin inhibitors- free immunosuppression therapy for pancreatic islet transplantation in patients with t1DM and chronic kidney disease. | The University of Chicago | Piotr Witkowski | Cures | 01-September-2025 to 31-August-2029 | $8,500,000.00 |
| Engineered Nanoparticles for Beta Cell-Targeted Therapeutics | The University of Chicago | Raghavendra Mirmira | Cures | 01-April-2023 to 31-March-2026 | $897,822.00 |
| Project Equity | The Sonia Nabeta Foundation | Vivian Nabeta | Mission | 01-May-2024 to 30-April-2026 | $245,172.00 |
| Triple therapy for T1DM with insulin, semaglutide and dapagliflozin | The Research Foundation of SUNY on behalf of University at Buffalo | Paresh Dandona | Improving Lives | 01-January-2019 to 31-March-2026 | $1,808,522.70 |
| Local delivery of immunomodulators to enable systemic immunosuppression-free efficient islet transplantation | The Regents of the University of California, San Francisco | Bhushan Kharbikar | Cures | 01-March-2024 to 28-February-2027 | $285,000.00 |
| Reducing Diabetes Distress in Adults with Type 1 Diabetes: A pragmatic trial in routine diabetes care. | The Regents of the University of California, San Francisco | Danielle Hessler | Improving Lives | 01-August-2023 to 31-July-2026 | $1,743,010.00 |
| Sparing ER stressed human beta cells with novel kinase inhibitors of the unfolded protein response (UPR) | The Regents of the University of California, San Francisco | Feroz Papa | Cures | 01-August-2023 to 31-July-2026 | $960,000.00 |
| Identification of novel targets to increase human beta cell proliferation | The Regents of the University of California, San Francisco | Gregory Ku | Cures | 01-December-2020 to 30-June-2026 | $975,000.00 |
| Mesh Oxygen Transporter for improved engraftment of human stem cell-derived pancreatic islet cells in the subcutaneous site | The Regents of the University of California, San Francisco | Hirotake Komatsu | Cures | 01-March-2024 to 30-June-2026 | $294,796.07 |
| Sequential multi-molecule release from nanofiber scaffolds for improved stem cell-derived islet transplantation under the skin | The Regents of the University of California, San Francisco | Hirotake Komatsu | Cures | 01-March-2024 to 31-July-2026 | $845,444.86 |